PHARMA TECHNOLOGY
ActiveSummary
PHARMA TECHNOLOGY has been active since 1991 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.3m and a net result of €3.8m. Equity remains stable across the filed financial years (±2.3% per year). Its solvency ranks better than 70% of 143 sector peers (NACE 32, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
24-01
Gazette deed
Resignations: DOLLINGER Martial (director) and NEXTGEN INVEST SRL (director)Appointments: ADFINITIS SRL (director) and NEXTGEN INVEST SRL (director) · Reappointment: PHARMA FLEX SA (managing director) · Permanent representatives: DOLLINGER Martial and BECKER Claire12 facts ▸
- General meeting, 16-09-2024
- Director resignation, DOLLINGER Martial (director)
- Director resignation, NEXTGEN INVEST SRL (director)
- Director appointment, ADFINITIS SRL (director)
- Director appointment, NEXTGEN INVEST SRL (director)
- Director reappointment, PHARMA FLEX SA (managing director)
- Permanent representative, DOLLINGER Martial (director)
- Permanent representative, BECKER Claire (director)
- Permanent representative, DOLLINGER Martial (managing director)
- Power of attorney, FIDUCIAIRE DIGITALE SRL
- Power of attorney, Benoît Meurmans
- Power of attorney, Nicolas Widar
About the unread acts
Of the 11 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 10 have not been read yet: what they contain is neither established nor disproved here.